Ovarian cancer is difficult to manage because the disease is most often diagnosed at an advanced stage when survival chances are poor. Early detection of ovarian cancer would increase long-term survival, since effective treatment modalities are available for early-onset disease. Screening with transvaginal ultrasound and serum CA 125 suggests promising results, but studies comparing mortality rates for screened vs unscreened populations are needed, and strategies must be developed for prevention or early diagnosis in order to control this disease process.
Get full access to this article
View all access options for this article.
References
1.
BoringC.C., SquiresT.S., TongT.Cancer statistics, 1994. CA Cancer J Clin.1994; 44: 7–26.
2.
ThigpenT., BradyM.F., OmuraG.A.Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer.1993; 71(Suppl 2): 606–614.
3.
HulkaB.S.Cancer screening: degrees of proof and practical application. Cancer.1988; 62(Suppl 8): 1776–1780.
4.
MacFarlaneC., SturgisM.C., FettermanF.C.Results of an experience in the control of cancer of the female pelvic organs: a report of a 15-year research. AMJ Obstet Gynecol.1956; 69: 294–301.
5.
HerbstA.L.The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol.1994; 170: 1099–1107.
6.
ZurawskiV.R.Jr, OrjaseterH., AndersenA.Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer.1988; 42: 677–680.
7.
JacobsI., DaviesA.P., BridgesJ.Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br Med J.1993; 306: 1030–1034.
8.
EinhornN., SjovallK., KnappR.C.Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol.1992; 80: 14–18.
9.
PatsnerB., MannW.J.The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol.1988; 159: 873–876.
10.
ChenD.X., SchwartzP.E., LiX.G.Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol.1988; 72: 23–27.
11.
SoperJ.T., HunterV.J., DalyL.Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol.1990; 75: 249–254.
12.
HosonoM.N., EndoK., SakaharaH.Different antigenic nature in apparently healthy women with high serum CA-125 levels compared with typical patients with ovarian cancer. Cancer.1992; 70: 2851–2856.
13.
CampbellS., BhanV., RoystonP.Transabdominal ultrasound screening for early ovarian cancer. Br Med J.1989; 299: 1363–1367.
14.
DePriestP.D., van NagelJ.R.Jr, GallionH.H.Ovarian cancer screening in symptomatic postmenopausal women. Gynecol Oncol.1993; 51: 205–209.
15.
GranbergS., WiklandM., JanssonI.Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol.1989; 35: 139–144.
16.
KarlanB.Y., PlattL.D.The current status of ultrasound and color Doppler imaging in screening for ovarian cancer. Gynecol Oncol.1994; 55: S28–S33.
17.
CarterJ., SaltzmanA., HartenbachE.Flow characteristics in benign and malignant gynecologic tumors using transvaginal color flow Doppler. Obstet Gynecol.1994; 83: 125–130.
18.
BourneT.H., CampbellS., ReynoldsK.M.Screening for early familial ovarian cancer with transvaginal ultrasonography and colour flow imaging. Br Med J.1993; 306: 1025–1029.
19.
KarlanB.Y., RaffelL.J., CrvenkovicG.A multidisciplinary approach to the early detection of ovarian carcinoma: Rationale, protocol design, and early results. Am J Obstet Gynecol.1993; 169: 494–501.
20.
MutoM.G., CramerD.W., BrownD.L.Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol.1993; 51: 12–20.
21.
van NagellJ.R.Jr. Ovarian cancer screening. Cancer.1991; 68: 679–680.
22.
BuyJ.N., GhossainM.A., SciotC.Epithelial tumors of the ovary: CT findings and correlation with US. Radiology.1991; 178: 811–818.
23.
BrownH.K., HazeltonT.R., ParsonsA.K.PC-based multiparameter full-color display for tissue segmentation in MRI of adnexal masses. J Comput Assist Tomogr.1993; 17: 993–1005.
24.
HubnerK.F., McDonaldT.W., NiehammerJ.G.Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F] deoxyglucose (2-[18f]FDG). Gynecol Oncol.1993; 51: 197–204.
25.
CohenC.J., JenningsT.S.Screening for ovarian cancer: the role of noninvasive imaging techniques. Am J Obstet Gynecol.1994; 170: 1088–1094.
26.
ThorA.D., EdgertonS.M.Monoclonal antibodies reactive with human breast or ovarian carcinoma; in vivo applications. Semin Nucl Med.1989; 14: 295–308.
27.
SurwitE.A., ChildersJ.M., KragD.N.Clinical assessment of 111 In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol.1993; 48: 285–292.
28.
ShohamZ.Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today?Fertil Steril.1994; 62: 433–448.
29.
VennW., LumleyJ., GilesG.Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet.1995; 346: 995–1000.
30.
LeungY., DePetrilloA.D.Etiology, epidemiology, risk and prognostic factors, screening, and imaging of gynecologic cancers. Curr Opin Oncol.1993; 5: 869–876.
31.
KerlikowskeK., BrownJ.S., GradyD.G.Should women with familial ovarian cancer undergo prophylactic oophorectomy?Obstet Gynecol.1992; 80: 700–707.
32.
HoulstonR.S., BourneT.H., CollinsW.P.Risk of ovarian cancer and genetic relationship to other cancers in families. Hum Hered.1993; 43: 111–115.
33.
LynchH.T., WatsonP., BewtraC.Hereditary ovarian cancer: heterogeneity in age at diagnosis. Cancer.1991; 67: 1460–1466.
HallJ.M., LeeM.K., NewmanB.Linkage of early-onset familial breast cancer to chromosome 17q21. Science.1990; 250: 1684–1689.
36.
FutrealP.A., LiuQ., Shattuck-EidensD.BRCA1 mutations in primary breast and ovarian carcinomas. Science.1994; 266: 120–122.
37.
MikiY., SwensenJ., Shattuck-EidensD.A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science.1994; 266: 66–71.
38.
BieseckerB.B., BoehnkeM., CalzoneK.Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. JAMA.1993; 269: 1970–1974.
39.
PetersJ.Breast cancer genetics: relevance to oncology practice. Cancer Cont: J M C C.1995; 2: 195–208.
40.
TobacmanJ.K., GreeneM.H., TuckerM.A.Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian-cancer-prone families. Lancet.1982; 2: 795–797.
41.
PiverM.S., JishiM.F., TsukadaY.Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer.1993; 71: 2751–2755.
42.
PiverM.S., BakerT.R., JishiM.F.Familial ovarian cancer: a report of 658 families from the Gilda Radner Familial Ovarian Cancer Registry 1981–1991. Cancer.1993; 71(Suppl 2): 582–588.
43.
LynchH.T., LynchJ.F., ConwayT.A.Genetics and gynecologic cancer. In: HoskinsW.J., PerezC.A., YoungR.C., eds. Principles and Practice of Gynecologic Oncology.Philadelphia, Pa: JB Lippincott Co; 1992.
44.
American College of Obstetricians and Gynecologists. Prophylactic bilateral oophorectomy to prevent epithelial ovarian cancer. ACOG criteria set #2. Washington DC: ACOG; 1994.
45.
GodwinA.K., HamiltonT.C., KnudsonA.J.Jr. Oncogenes and antioncogenes. In: HoskinsW.J., PerezC.A., YoungR.C., eds. Principles and Practice of Gynecologic Oncology.Philadelphia, Pa: JB Lippincott Co; 1992.
46.
BartonD.P., BlanchardD.K., WellsA.F.Expression of interleukin-2 receptor alpha (IL-2Ra) mRNA and protein in advanced epithelial ovarian cancer. Anticancer Res.1994; 14: 761–772.
47.
American College of Obstetricians and Gynecologists. Routine cancer screening. ACOG Technical Bulletin 128. Washington, DC: ACOG; 1993.
